Unofficial Copy 2003 Regular Session
J2 3lr1845

By: **Delegates Haynes, Anderson, Barkley, Benson, Branch, Bromwell, Burns, Cane, Cardin, Carter, Conroy, D. Davis, Donoghue, Doory, Dumais, Fulton, Gaines, Goldwater, Gordon, Griffith, Hammen, Harrison, Holmes, Howard, Hubbard, Jones, Kaiser, Kelley, Kelly, Kirk, Lee, Love, Madaleno, Mandel, Marriott, McDonough, McHale, Menes, Moe, Murray, Nathan-Pulliam, Niemann, Oaks, Paige, Parker, Patterson, Pendergrass, Proctor, Ramirez, Rawlings, Ross, Rudolph, Smigiel, Taylor, Trueschler, F. Turner, V. Turner, Vaughn, Weldon, ~~and Zirkin~~ Zirkin, Boutin, Costa, Elliott, Kach, Morhaim, Redmer, and Rosenberg**

Introduced and read first time: February 7, 2003
Assigned to: Health and Government Operations

Committee Report: Favorable with amendments
House action: Adopted
Read second time: March 18, 2003

CHAPTER_____

AN ACT concerning

Pharmacists ~~and Pharmacies~~ - Practice - ~~Advice of~~ Information on Generic Drug Option

FOR the purpose of requiring ~~an employee of a pharmacy or~~ a pharmacist to ~~advise~~ inform retail consumers of generically equivalent drugs; requiring ~~an employee of a pharmacy or~~ a pharmacist to ~~advise~~ inform retail consumers of the approximate cost difference of generically equivalent drugs as compared to brand name drugs; requiring the Board to adopt procedures to assure compliance with this Act; providing for certain exceptions to the requirements of this Act; and generally relating to providing information on generic drug options.

BY repealing and reenacting, with amendments,
Article - Health Occupations
Section 12-504
Annotated Code of Maryland
(2000 Replacement Volume and 2002 Supplement)

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:

Article - Health Occupations

12-504.

(a) In this section, "brand name" means the proprietary name a manufacturer places on a drug or device product or its container.

(B) (1) SUBJECT TO THE PROVISIONS OF THIS SUBTITLE, ~~AN EMPLOYEE OF THE PHARMACY OR~~ A PHARMACIST SHALL ~~ADVISE THE~~ INFORM A RETAIL CONSUMER TO THE BEST OF THE PHARMACIST'S KNOWLEDGE OF THE AVAILABILITY OF A GENERICALLY EQUIVALENT DRUG AND SHALL ~~ADVISE THE~~ INFORM A RETAIL CONSUMER OF THE APPROXIMATE COST DIFFERENCE AS COMPARED TO THE BRAND NAME DRUG.

(2) THE BOARD SHALL ADOPT PROCEDURES FOR:

(I) A CONSUMER TO NOTIFY THE BOARD WHEN A PHARMACIST FAILS TO PROVIDE THE INFORMATION REQUIRED UNDER PARAGRAPH (1) OF THIS SUBSECTION; AND

(II) ADVISING A PHARMACIST TO BRING THE PHARMACIST INTO COMPLIANCE WITH THE REQUIREMENTS OF PARAGRAPH (1) OF THIS SUBSECTION.

(3) PARAGRAPH (1) OF THIS SUBSECTION DOES NOT APPLY:

(I) TO A PRESCRIPTION THAT IS WRITTEN FOR A GENERIC DRUG;

(II) WHEN THE AUTHORIZED PRESCRIBER STATES EXPRESSLY THAT THE PRESCRIPTION IS TO BE DISPENSED ONLY AS DIRECTED;

(III) TO A PHARMACIST WHO WORKS IN A PHARMACY, WHETHER CENTRALIZED OR DECENTRALIZED, WHICH PRIMARILY SERVES PUBLIC OR PRIVATE INSTITUTIONAL RECIPIENTS; OR

(IV) WHEN THE COST OF THE PRESCRIPTION IS REIMBURSED BY A THIRD PARTY PAYER, INCLUDING MEDICAL ASSISTANCE.

[(b)] (C) A pharmacist may substitute a generically equivalent drug or device product, of the same dosage form and strength, for any brand name drug or device product prescribed, if:

(1) The authorized prescriber does not state expressly that the prescription is to be dispensed only as directed;

(2) The substitution is recognized in the United States Food and Drug Administration's current list of approved drug or device products with therapeutic equivalence evaluations; and

(3) The consumer is charged less for the substituted drug or device than the price of the brand name drug or device.

[(c)] (D) If a drug or device product is substituted under this section, the pharmacist shall:

(1) Notify the patient in writing that the drug or device product dispensed is a generic equivalent of the prescribed drug or device product; and

(2) Record on the prescription and keep a record of the name and manufacturer of the substituted drug or device product.

[(d)] (E) The Department may list any additional drug or device products that are determined by the Department to meet requirements that are adequate to assure product quality and therapeutic equivalence, after an opportunity for public comment as provided in Title 10, Subtitle 1 of the State Government Article.

[(e)] (F) The Department may disqualify a drug or device product on the United States Food and Drug Administration's current list from being used in Maryland as a generic substitute if the Department determines that the drug or device is therapeutically nonequivalent or has a negative physical or biological effect on the consumer of that drug or device product:

(1) After providing an opportunity for public comment as provided in Title 10, Subtitle 1 of the State Government Article; or

(2) Prior to providing an opportunity for public comment, if the Department believes that a particular generic drug or device product constitutes an imminent danger to the public health, safety or welfare, and the Department:

(i) Provides an opportunity for public comment as provided in Title 10, Subtitle 1 of the State Government Article within 30 days of disqualifying the drug or device product; and

(ii) After providing an opportunity for public comment, determines whether the drug or device product should remain disqualified.

[(f)] (G) For a drug or device product that the Department has disqualified from being used in Maryland as a generic substitute under subsection [(e)] (F) of this section, the Department shall provide an opportunity for public comment as provided in Title 10, Subtitle 1 of the State Government Article before reinstating the drug or device product for use in Maryland as a generic substitute.

[(g)] (H) A pharmacist who substitutes a drug or device product in compliance with this section incurs no greater liability in filling the prescription by dispensing the equivalent drug or device product than would be incurred in filling the prescription by dispensing the prescribed brand name drug or device.

SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect October 1, 2003.